2021年尼日利亚AstraZeneca与Moderna新冠疫苗接种者队列事件监测的可行性及反应原性与不良事件评估
未发现非预期不良事件模式,11例死亡无证据与疫苗相关,证明中低收入国家在大规模接种中实施队列事件监测可行。
要点
- 首剂后0-7天内,AstraZeneca接种者局部反应43.5%、全身反应39.8%,Moderna分别为72.4%和42.8%。
- 第二剂后,AstraZeneca接种者局部反应23%、全身反应18.7%,Moderna分别为49.7%和42.2%。
- 全部入组者中11例死亡,无证据提示与疫苗相关;未发现非预期不良事件模式。
核心结论
- 未检测到非预期的不良事件模式,为尼日利亚成人接种这些新冠疫苗提供了额外安全性数据。
- 实施队列事件监测是可行的,可能对中低收入国家引入疫苗的安全性监测有价值。
研究设计与样本
- 在尼日利亚6个州参与研究的卫生机构中,纳入2021年9月至10月接种首剂授权新冠疫苗、年龄≥18岁且可使用手机的参与者。
- 数据收集员在第0、3、7天及之后每7天通过电话访谈参与者,持续3个月;若接种第二剂则重新开始相同随访计划。
- 计算参与者报告的新冠疫苗接种后不良事件比例,并对死亡病例使用世界卫生组织因果关系指南进行调查和因果关系评估。
主要发现
- 共入组12317名参与者,其中AstraZeneca 6990名、Moderna 5327名。
- 首剂后0-7天完成随访访谈者中,AstraZeneca组2685/6167(43.5%)报告局部反应、2456/6167(39.8%)报告全身反应;Moderna组3533/4879(72.4%)报告局部反应、2087/4879(42.8%)报告全身反应。
- AstraZeneca组3891/6990(55.7%)和Moderna组3978/5327(72.8%)接种者接受了第二剂;其中AstraZeneca组897/3891(23%)报告局部反应、727/3891(18.7%)报告全身反应,Moderna组1979/3978(49.7%)报告局部反应、1680/3978(42.2%)报告全身反应。
- 全部入组者中11例死亡,无证据提示任何死亡与疫苗相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To generate COVID-19 vaccine safety data in Nigeria, passive reporting was supplemented with cohort event monitoring (CEM), an active surveillance system. We described reactogenicity within 7 days and adverse events up to 3 months after each AstraZeneca or Moderna COVID-19 vaccine dose while assessing the feasibility of implementing CEM in a low- to middle-income country (LMIC) during a mass vaccination campaign. METHODS: Participants were aged ≥18 years with access to mobile phones who received the first dose of an authorized COVID-19 vaccine from participating health facilities in 6 states of Nigeria during September and October 2021. Data collectors interviewed participants via phone on days 0, 3, 7, and thereafter every 7 days for 3 months. The same schedule was restarted if a participant received a second vaccine dose. Proportions of participant-reported adverse events following COVID-19 vaccine receipt were calculated. Investigation and causality assessment were conducted on deaths using the World Health Organization causality guidelines. RESULTS: We enrolled 12,317 participants (AstraZeneca 6990; Moderna 5327); 6167/6990 (88.2 %) AstraZeneca and 4879/5327 (91.6 %) Moderna recipients completed a follow-up interview days 0-7 after the first dose; among them, 2685/6167 (43.5 %) AstraZeneca and 3533/4879 (72.4 %) Moderna recipients reported local reactions and 2456/6167 (39.8 %) AstraZeneca and 2087/4879 (42.8 %) Moderna recipients reported systemic reactions. Overall, 3891/6990 (55.7 %) AstraZeneca and 3978/5327 (72.8 %) Moderna recipients received a second dose of COVID-19 vaccine, among whom 897/3891 (23 %) AstraZeneca and 1979/3978 (49.7 %) Moderna recipients reported local reactions and 727/3891 (18.7 %) AstraZeneca and 1680/3978 (42.2 %) Moderna recipients reported systemic reactions. Among all enrolled, 11 died; there was no evidence to suggest any deaths were vaccine-related. CONCLUSIONS: No unexpected patterns of adverse events were detected, providing additional data on the safety of these COVID-19 vaccines in Nigerian adults. We demonstrated that implementing CEM was feasible and may be valuable for safety monitoring of vaccines introduced in LMICs.
引用
- Bolu O, Alo OD, Iwara E, et al. Feasibility of cohort event monitoring and assessment of reactogenicity and adverse events among a cohort of AstraZeneca and Moderna COVID-19 vaccine recipients in Nigeria, 2021. Vaccine. 2025. PMID: 40073670. doi:10.1016/j.vaccine.2025.126907
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。